# China-Administration of Nicorandil Group（CHANGE）

> **NCT03445728** · PHASE4 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 238 (actual)

## Conditions studied

- Myocardial Infarction
- Percutaneous Coronary Intervention
- Nicorandil

## Interventions

- **DRUG:** Nicorandil
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03445728
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-24
- **Primary completion:** 2020-07-31
- **Final completion:** 2021-10-01
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445728, "China-Administration of Nicorandil Group（CHANGE）". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03445728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*